Skip to content

Upper Extremity Exercise Capacity Of Breast Cancer

Comparison Of Upper Extremity Exercise Capacity Of Breast Cancer Patients With Healthy Individuals

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06859593
Enrollment
48
Registered
2025-03-05
Start date
2025-03-01
Completion date
2025-06-01
Last updated
2025-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer Survivor, Healty Controls

Keywords

breast cancer, upper extremity, 6-minute pegboard and ring test, exercise capacity

Brief summary

Breast cancer is one of the most common cancers among women worldwide, with an incidence rate of up to 16%. Although survival can be improved with early diagnosis and more effective therapies, physical complications such as lymphedema, upper extremity dysfunction and chronic pain are common during and/or after breast cancer treatments. In addition, lymphedema can cause symptoms such as decreased muscle strength and range of motion of the upper extremity, pain and fatigue, resulting in activity limitations and decreased functional level of the upper extremity.

Detailed description

Breast cancer is one of the most common cancers among women worldwide, with an incidence rate of up to 16%. While the breast cancer survival rate is 80% in developed countries, this rate varies between 40-60% in low-middle income countries. Although survival can be increased with early diagnosis and more effective therapies, physical complications such as lymphedema, upper extremity dysfunction and chronic pain are frequently observed during and/or after breast cancer treatments. Upper extremity lymphedema that develops after breast cancer treatment usually affects the glenohumeral joint by increasing the tension in the tendons of the rotator cuff muscles and disrupting the scapulohumeral rhythm. In addition, lymphedema may cause symptoms such as decreased muscle strength and range of motion of the upper extremity, pain and fatigue, resulting in activity limitations and decreased functional level of the upper extremity. Kinesiophobia (fear-avoidance reaction to activity), which may develop in patients in relation to the affected extremity, is another factor in decreased capacity of the upper extremity. Patients may restrict the use of their extremities to prevent aggravation of lymphedema. Decreased functional capacity is common after breast cancer treatment. The '6 Minute Pegboard and Ring Test-6PBRT' is a valid and reliable, useful, practical and easy-to-administer test that evaluates unsupported arm endurance in breast cancer patients, patients with COPD, patients with asthma and healthy individuals. For the test, patients are asked to carry as many rings as possible within 6 minutes and the number of rings carried for 6 minutes is recorded as a score. In a study conducted in patients with mild to very severe COPD, it was shown that there was a positive correlation between the 6PBRT score and activity counts assessed by accelerometry. In addition, the 6PBRT score showed a clear relationship with upper extremity ROM and it was concluded that the 6PBRT test can be used as a suitable test for predicting and demonstrating improvement of ROM in pulmonary rehabilitation programs. Therefore, the aim of this study was to test both arm endurance and arm exercise capacity of patients with breast cancer using the 6PBRT test and to compare them with healthy individuals to understand how much they are affected compared to healthy individuals. As a secondary aim of the study, it is planned to investigate the relationship between lymph edema severity and anthropometric measurements and upper extremity activities and arm exercise capacity in the group with breast cancer.

Interventions

DIAGNOSTIC_TESTUpper Extremity Exercise Capacity, 6-Minute Pegboard And Ring Test

Upper Extremity Exercise Capacity

Sponsors

Hacettepe University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

Breast Cancer Group: 1. Being between 18-65 years of age, 2. Volunteering to participate in the research, 3. Stage I-III breast cancer, 4. At least 15 months after breast cancer surgery, 5. Six months after active breast cancer treatment (i.e. surgery/chemotherapy), 6. No problems in reading and/or understanding the scales and being able to cooperate with the tests, Healthy group: 1. Age between 18-65 years, 2. Volunteering to participate in the research, 3. No problems in reading and/or understanding the scales and being able to cooperate with the tests.

Exclusion criteria

Breast Cancer Group: 1. Presence of active infection, 2. Musculoskeletal and neurological diseases that may affect exercise performance, symptomatic heart disease, 3. Having a neurological disease or other clinical diagnosis that may affect cognitive status. Healthy group: 1. Having any orthopedic or neuromuscular condition that would interfere with walking or exercise performance, 2. Having any chronic disease or psychiatric disorders or mental impairments that may interfere with cooperation or compliance with exercise tests

Design outcomes

Primary

MeasureTime frameDescription
Upper Extremity Exercise CapacityOne Year6-Minute Pegboard and Ring Test

Secondary

MeasureTime frameDescription
Evaluation of Upper Extremity FunctionalityOne YearQuestionnaire Quick Disability of the Arm, Shoulder, and Hand (Quick DASH) The score ranges from 0 to 100. A higher score reflects more severe upper extremity dysfunction, and the cutoff scores are 0-15 for normal, 16-40 for having problems but working, and more than 40 for being unable to work
Lymphedema EvaluationOne YearArm circumference measurement
Measurement of arm length, arm and forearm circumferenceOne YearThe circumference and length measurements of the participants' dominant and non-dominant arm will be measured using a tape measure

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026